Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+)-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates

Clinical and Experimental Immunology

Volumn 164, Issue 2, 2011, Pages 265-274

  Poirier, N ^a   Haudebourg, T ^a   Brignone, C ^b   Dilek, N ^a   Hervouet, J ^a   Minault, D ^a   Coulon, F ^a   de Silly, R V ^a   Triebel, F ^b   Blancho, G ^a   Vanhove, B ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Immutep SA   (France)

Author keywords

Delayed type hypersensitivity; LAG 3; Primate; Therapeutic antibodies

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC MONOCLONAL ANTIBODY A9H12; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DELAYED HYPERSENSITIVITY; GENE; GENE LOSS; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION GENE 3; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN INFLAMMATION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 79953768104     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04329.x     Document Type: Article

References (29)

1. Salvana EM, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009; 22:274-90.
2. Thomas-Vaslin V, Bellier B, Cohen JL etal. Prolonged allograft survival through conditional and specific ablation of alloreactive T cells expressing a suicide gene. Transplantation 2000; 69:2154-61.
3. Triebel F, Jitsukawa S, Baixeras Eetal.LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990; 171:1393-405.
4. Triebel F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 2003; 24:619-22.
5. Huard B, Mastrangeli R, Prigent Petal.Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci USA 1997; 94:5744-9.
6. Avice MN, Sarfati M, Triebel F, Delespesse G, Demeure CE. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J Immunol 1999; 162:2748-53.
7. Andreae S, Piras F, Burdin N, Triebel F. Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 2002; 168:3874-80.
8. Workman CJ, Wang Y, El Kasmi KCetal.LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 2009; 182:1885-91.
9. Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 1994; 39:213-17.
10. Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated LAG-3 molecules inhibit CD3/TCR signaling. J Immunol 1998; 161:4058-65.
11. Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 2003; 33:970-9.
12. Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005; 115:170-8.
13. Huang CT, Workman CJ, Flies Detal.Role of LAG-3 in regulatory T cells. Immunity 2004; 21:503-13.
14. Okamura T, Fujio K, Shibuya Metal.CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci USA 2009; 106:13974-9.
15. Haudebourg T, Dugast AS, Coulon Fetal.Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance. Transplantation 2007; 84:1500-6.
16. Black CA. Delayed type hypersensitivity: current theories with an historic perspective. Dermatol Online J 1999; 5:7.
17. Coll JM. Injection of physiological saline facilitates recovery of ascitic fluids for monoclonal antibody production. J Immunol Methods 1987; 104:219-22.
18. Kirk A, Harlan D, Amstrong Netal.CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94:8789-94.
19. Guillonneau C, Seveno C, Dugast ASetal.Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007; 179:8164-71.
20. Monk NJ, Hargreaves RE, Marsh JEetal.Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003; 9:1275-80.
21. Ferrant JL, Benjamin CD, Cutler AHetal.The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol 2004; 16:1583-94.
22. Mirabet M, Barrabes JA, Quiroga A, Garcia-Dorado D. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol Immunol 2008; 45:937-44.
23. Strom TB, Kelley VR, Woodworth TG, Murphy JR. Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules. Immunol Rev 1992; 129:131-63.
24. Benghiat FS, Graca L, Braun MYetal.Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression. Transplantation 2005; 79:648-54.
25. Camisaschi C, Casati C, Rini Fetal.LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010; 184:6545-51.
26. Tomura M, Honda T, Tanizaki Hetal.Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest 2010; 120:883-93.
27. Maddison SE, Hicklin MD, Conway BP, Kagan IG. Transfer factor: delayed hypersensitivity to Schistosoma mansoni and tuberculin in Macaca mulatta. Science 1972; 178:757-9.
28. Cordoba F, Wieczorek G, Preussing E, Bigaud M. Modeling of delayed type hypersensitivity (DTH) in the non-human primate (NHP). Drug Discov Today 2008; 5:63-71.
29. Kobayashi K, Kaneda K, Kasama T. Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 2001; 53:241-5.